|
|
Article: Circassia Raises GBP11 Million ($21.8 Million) in Oversubscribed Second Round Funding.
- Article from:
- PR Newswire
- Article date:
- January 29, 2008
CopyrightCOPYRIGHT 2008 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
OXFORD, England, January 29 /PRNewswire/ -- Circassia Ltd, a specialty biopharmaceutical company focused on controlling immune system responses, announced today that it has successfully raised GBP11 million ($21.8 million) in an oversubscribed second round funding. The investment syndicate includes new investors Goldman Sachs and Invesco Perpetual, as well as existing investors, including Imperial Innovations and Lansdowne Partners.
"Completing this financing is a testament to the potential of Circassia's business, management and technology," said Steve Harris, Circassia's CEO. "We have made good progress advancing our anti-allergy products during the last year, ...
Related newspaper, magazine, and journal articles:
|
|
Article: Circassia Initiates Phase II Clinical Study With Novel ...
PR Newswire;
February 27, 2008 ;
700+ words
... ... allergy product range," said Steve Harris, Circassia's CEO. "This study is particularly ... information please visit http://www.circassia.co.uk/. CONTACT: Contacts: Steve Harris, CEO Circassia,Tel: +44-1865-784-574 ...
|
|